Ftse Mib
33.186,89
0,00%
DAX
18.210,55
0,26%
S&P 500
5.482,87
0,09%
NASDAQ
17.858,68
0,30%
Bitcoin
61.484,91
-0,20%
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ TransCode Therapeutics Inc (RNAZ) TransCode Therapeutics Inc (RNAZ) Notizie

RNAZ

TransCode Therapeutics (RNAZ)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RNAZ
DataOraFonteTitoloSimboloCompagnia
18/06/202422:16Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RNAZTransCode Therapeutics Inc
14/06/202414:00Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
13/06/202423:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202414:45Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RNAZTransCode Therapeutics Inc
10/06/202413:00GlobeNewswire Inc.Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing RequirementsNASDAQ:RNAZTransCode Therapeutics Inc
29/05/202415:15GlobeNewswire Inc.TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
20/05/202422:00Edgar (US Regulatory)Form DEFR14A - Revised definitive proxy soliciting materialsNASDAQ:RNAZTransCode Therapeutics Inc
13/05/202414:30GlobeNewswire Inc.TransCode Therapeutics Open Letter to ShareholdersNASDAQ:RNAZTransCode Therapeutics Inc
10/05/202422:50Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
15/04/202415:00GlobeNewswire Inc.TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid TumorsNASDAQ:RNAZTransCode Therapeutics Inc
03/04/202415:10GlobeNewswire Inc.TransCode Therapeutics Reports 2023 Results; Provides Business UpdateNASDAQ:RNAZTransCode Therapeutics Inc
28/03/202413:30GlobeNewswire Inc.TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical OfficerNASDAQ:RNAZTransCode Therapeutics Inc
11/03/202414:00GlobeNewswire Inc.TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer TreatmentNASDAQ:RNAZTransCode Therapeutics Inc
06/03/202422:15GlobeNewswire Inc.TransCode Therapeutics To Present At 2024 RNA Leaders Europe CongressNASDAQ:RNAZTransCode Therapeutics Inc
20/02/202414:00GlobeNewswire Inc.TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode’s RIG-I Agonist ImmunotherapeuticNASDAQ:RNAZTransCode Therapeutics Inc
15/02/202422:00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
31/01/202422:05GlobeNewswire Inc.Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders’ Equity Requirement and Continued Listing on The Nasdaq Stock MarketNASDAQ:RNAZTransCode Therapeutics Inc
29/01/202414:30GlobeNewswire Inc.TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for CancerNASDAQ:RNAZTransCode Therapeutics Inc
22/01/202422:45GlobeNewswire Inc.TransCode Therapeutics Announces Closing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
20/01/202403:57Edgar (US Regulatory)Form 424B4 - Prospectus [Rule 424(b)(4)]NASDAQ:RNAZTransCode Therapeutics Inc
19/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:RNAZTransCode Therapeutics Inc
18/01/202419:27GlobeNewswire Inc.TransCode Therapeutics Announces Pricing of $7.25 Million Public OfferingNASDAQ:RNAZTransCode Therapeutics Inc
18/01/202416:39Edgar (US Regulatory)Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]NASDAQ:RNAZTransCode Therapeutics Inc
12/01/202422:05GlobeNewswire Inc.TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEONASDAQ:RNAZTransCode Therapeutics Inc
11/01/202414:22Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:RNAZTransCode Therapeutics Inc
11/01/202414:00GlobeNewswire Inc.TransCode Therapeutics Announces 1-for-40 Reverse Stock SplitNASDAQ:RNAZTransCode Therapeutics Inc
04/01/202414:05GlobeNewswire Inc.TransCode Therapeutics Publishes Open Letter Outlining Company’s Progress and ObjectivesNASDAQ:RNAZTransCode Therapeutics Inc
18/12/202322:28Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:RNAZTransCode Therapeutics Inc
12/12/202314:30GlobeNewswire Inc.TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138NASDAQ:RNAZTransCode Therapeutics Inc
07/12/202322:30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:RNAZTransCode Therapeutics Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:RNAZ

La tua Cronologia

NASDAQ
BBLGW
Bone Biologics
BIT
AIW
Almawave
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network